


Express Mail Label No.: EV058074673US
Date of Deposit: March 7, 2002

Attorney Docket No. 21402-175 CIP (Cura-475CIP)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Edinger, et al.
SERIAL NUMBER: 09/997,425 EXAMINER: Not Yet Assigned
FILING DATE: November 29, 2001 ART UNIT:
FOR: Novel Polypeptides and Nucleic Acids Encoding Same

Box IDS
Assistant Commissioner for Patents
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages) in duplicate;
3. Copies of cited references C1-19; and
4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 21402-175 CIP (Cura-475 CIP). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No 39,529

Attorney for Applicant

c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 7, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8

APPLICANTS: Edinger, et al.
SERIAL NUMBER: 09/997,425 EXAMINER: Not Yet Assigned
FILING DATE: November 29, 2001 ART UNIT:
FOR: Novel Polypeptides and Nucleic Acids Encoding Same

BOX IDS
Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Edinger, et al.
U.S.S.N.: 09/997,425

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-175 CIP.

Respectfully submitted,

 72,862

Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: March 7, 2002

TRA 1639186v1

Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.




Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/997,425
	Filing Date	11/29/2001
	First Named Inventor	Edinger
	Group Art Unit	
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	21402-175 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Alderborn, et al. (2000). "Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing." <i>Genome Res</i> 10(8): 1249-58.
	C2	Anholt, et al. (1986). "The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane." <i>J Biol Chem</i> 261(2): 576-83.
	C3	Barbaccia, et al. (1986). "Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease." <i>Arch Gen Psychiatry</i> 43(12): 1143-7.
	C4	de Mateos-Verchere, et al. (2001). "The octadecaneuropeptide [diazepam-binding inhibitor (33-50)] exerts potent anorexigenic effects in rodents." <i>Eur J Pharmacol</i> 414(2-3): 225-31.
	C5	Edgar, et al. (1999). "A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals." <i>Mol Psychiatry</i> 4(2): 173-8.
	C6	GenBank Accession Number: AL133064 (18-FEB-2000)
	C7	GenBank Accession Number: CAC24873 (22-JAN-2001)
	C8	GenBank Accession Number: CAC24877 (22-JAN-2001)
	C9	GenBank Accession Number: P07106 (16-OCT-2001)
	C10	Gooday, et al. (1995). "Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy." <i>Psychopharmacology (Berl)</i> 119(3): 295-8.
	C11	Guarneri, et al. (1990). "A study of diazepam binding inhibitor (DBI) processing products in human cerebrospinal fluid and in postmortem human brain." <i>Neuropharmacology</i> 29(5): 419-28.
	C12	Ohkuma, et al. (2001). "Alterations in cerebral diazepam binding inhibitor expression in drug dependence: a possible biochemical alteration common to drug dependence." <i>Life Sci</i> 68(11): 1215-22.
	C13	Rothstein, et al. (1989). "Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy." <i>Ann Neurol</i> 26(1): 57-62.
	C14	Roy, et al. (1989). "Diazepam-binding inhibitor and corticotropin-releasing hormone in cerebrospinal fluid." <i>Acta Psychiatr Scand</i> 80(3): 287-91.



OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C15	Stepien, et al. (1993). "Immunomodulatory properties of diazepam-binding inhibitor: effect on human interleukin-6 secretion, lymphocyte proliferation and natural killer cell activity in vitro." <i>Neuropeptides</i> 25(3): 207-11.
	C16	Suk, et al. (1999). "Molecular cloning and expression of a novel human cDNA related to the diazepam binding inhibitor." <i>Biochim Biophys Acta</i> 1454(1): 126-31
	C17	SWALL (SPTR) Accession Number: Q9CW41 (1-JUN-2001)
	C18	SWALL (SPTR) Accession Number: Q9UFB5 (1-MAY-2000)
	C19	Wootton and Federhen (1996). "Analysis of compositionally biased regions in sequence databases." <i>Methods Enzymol</i> 266: 554-71.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.